Bio-Path (NASDAQ:BPTH) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Bio-Path (NASDAQ:BPTH) in a report issued on Monday morning. The brokerage issued a sell rating on the stock.

Bio-Path Stock Performance

NASDAQ:BPTH opened at $0.18 on Monday. Bio-Path has a twelve month low of $0.12 and a twelve month high of $4.55. The firm has a 50-day moving average price of $0.16 and a two-hundred day moving average price of $0.59.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.